Crescent Grove Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.21M | Sell |
64,244
-2,780
| -4% | -$347K | 0.79% | 33 |
|
|
2025
Q4 | $8.17M | Sell |
67,024
-3,006
| -4% | -$345K | 0.76% | 30 |
|
|
2025
Q3 | $7.02M | Sell |
70,030
-9,645
| -12% | -$869K | 0.67% | 32 |
|
|
2025
Q2 | $6.61M | Sell |
79,675
-4,440
| -5% | -$354K | 0.64% | 35 |
|
|
2025
Q1 | $6.82M | Sell |
84,115
-7,530
| -8% | -$673K | 0.71% | 31 |
|
|
2024
Q4 | $8.25M | Sell |
91,645
-5,573
| -6% | -$540K | 0.82% | 29 |
|
|
2024
Q3 | $9.61M | Sell |
97,218
-6,285
| -6% | -$618K | 0.98% | 23 |
|
|
2024
Q2 | $9.6M | Sell |
103,503
-10,331
| -9% | -$926K | 1.05% | 24 |
|
|
2024
Q1 | $10.8M | Sell |
113,834
-6,927
| -6% | -$643K | 1.13% | 22 |
|
|
2023
Q4 | $10.8M | Sell |
120,761
-2,780
| -2% | -$206K | 1.2% | 21 |
|
|
2023
Q3 | $9.02M | Sell |
123,541
-6,494
| -5% | -$519K | 1.12% | 21 |
|
|
2023
Q2 | $10.8M | Sell |
130,035
-517
| -0.4% | -$43.2K | 1.16% | 21 |
|
|
2023
Q1 | $9.95M | Buy |
130,552
+5,048
| +4% | +$419K | 1.15% | 21 |
|
|
2022
Q4 | $10.4M | Sell |
125,504
-11,061
| -8% | -$895K | 1.08% | 22 |
|
|
2022
Q3 | $10.8M | Buy |
136,565
+1,557
| +1% | +$131K | 1.25% | 17 |
|
|
2022
Q2 | $10M | Buy |
135,008
+3,820
| +3% | +$287K | 1.06% | 19 |
|
|
2022
Q1 | $11.8M | Buy |
131,188
+22,576
| +21% | +$2.08M | 1.15% | 18 |
|
|
2021
Q4 | $12.2M | Sell |
108,612
-10,735
| -9% | -$1.29M | 1.14% | 19 |
|
|
2021
Q3 | $15M | Buy |
119,347
+20,769
| +21% | +$2.67M | 1.59% | 14 |
|
|
2021
Q2 | $13.3M | Buy |
98,578
+11,842
| +14% | +$1.56M | 1.4% | 15 |
|
|
2021
Q1 | $11.8M | Sell |
86,736
-1,433
| -2% | -$215K | 1.38% | 16 |
|
|
2020
Q4 | $12.4M | Buy |
88,169
+3,095
| +4% | +$396K | 1.62% | 13 |
|
|
2020
Q3 | $9.48M | Buy |
85,074
+1,894
| +2% | +$212K | 1.89% | 12 |
|
|
2020
Q2 | $9.31M | Sell |
83,180
-2,310
| -3% | -$228K | 1.97% | 11 |
|
|
2020
Q1 | $6.62M | Sell |
85,490
-4,043
| -5% | -$358K | 1.47% | 12 |
|
|
2019
Q4 | $8.52M | Sell |
89,533
-3,841
| -4% | -$332K | 1.48% | 12 |
|
|
2019
Q3 | $7.12M | Sell |
93,374
-20,655
| -18% | -$1.72M | 1.37% | 14 |
|
|
2019
Q2 | $10M | Sell |
114,029
-2,768
| -2% | -$236K | 1.88% | 8 |
|
|
2019
Q1 | $10.6M | Buy |
116,797
+12,878
| +12% | +$1.1M | 2.17% | 7 |
|
|
2018
Q4 | $7.46M | Sell |
103,919
-35,533
| -25% | -$2.86M | 1.59% | 11 |
|
|
2018
Q3 | $13.4M | Buy |
139,452
+5,208
| +4% | +$505K | 2.89% | 6 |
|
|
2018
Q2 | $12.8M | Buy |
134,244
+4,917
| +4% | +$452K | 3.17% | 6 |
|
|
2018
Q1 | $11.3M | Buy |
129,327
+11,057
| +9% | +$1.01M | 2.78% | 6 |
|
|
2017
Q4 | $10M | Buy |
118,270
+26,290
| +29% | +$2.2M | 2.52% | 7 |
|
|
2017
Q3 | $7.96M | Buy |
91,980
+3,948
| +4% | +$317K | 2.04% | 8 |
|
|
2017
Q2 | $6.79M | Buy |
+88,032
| New | +$6.24M | 1.96% | 9 |
|
Other funds holding XBI
Crescent Grove Advisors's XBI Position: Q1 2026 in Review
Crescent Grove Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 4.1% in Q1 2026, selling an estimated $347K and leaving 64,244 shares worth $8.21M. The position accounts for 0.79% of the portfolio, ranked #33.
Crescent Grove Advisors first reported a position in XBI in Q2 2017 and has held it in 36 quarters since. The position peaked at $15M in Q3 2021. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Crescent Grove Advisors held 64,244 shares of State Street SPDR S&P Biotech ETF worth $8.21M as of Q1 2026.
- Crescent Grove Advisors sold 2,780 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $347K.
- State Street SPDR S&P Biotech ETF made up 0.79% of Crescent Grove Advisors's portfolio in Q1 2026, its #33 holding.
- Crescent Grove Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and has held it in 36 quarters since.
- Crescent Grove Advisors's State Street SPDR S&P Biotech ETF position peaked at $15M in Q3 2021.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Crescent Grove Advisors's 13F filing for Q1 2026, filed 6 May 2026.